NASDAQ : RNAZ
TransCode Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.63 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 27.60M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 27.60M |
| Enterprise Value | 19.87M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 16.93M |
| Shares Outstanding | 16.93M |
| Shares Change (YoY) | +246.69% |
| Shares Change (QoQ) | +4.39% |
| Owned by Insiders (%) | 2.03% |
| Owned by Institutions (%) | 0.52% |
| Float | 2.15M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.20 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.97 |
| Quick Ratio | 1.55 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3,900.25 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -59.28% |
| Return on Assets (ROA) | -19.90% |
| Return on Invested Capital (ROIC) | -21.84% |
| Return on Capital Employed (ROCE) | -17.42% |
| Weighted Average Cost of Capital (WACC) | 10.92% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.86M |
| Employee Count | 12 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 457,677 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.26 |
| 52-Week Price Change | -86.34% |
| 50-Day Moving Average | 1.84 |
| 200-Day Moving Average | 6.15 |
| Relative Strength Index (RSI) | 40.86 |
| Average Volume (20 Days) | 35,647 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 54,968 |
| Short Previous Month | 52,062 |
| Short % of Shares Out | 0.32% |
| Short % of Float | 2.55% |
| Short Ratio (days to cover) | 1.03 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -25.36M |
| Pretax Income | -42.38M |
| Net Income | -46.28M |
| EBITDA | -25.26M |
| EBIT | -25.36M |
| Earnings Per Share (EPS) | -$51.08 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 8.38M |
| Total Debt | 652,411 |
| Net Cash | 7.73M |
| Net Cash Per Share | $0.46 |
| Equity (Book Value) | 138.36M |
| Book Value Per Share | -27.38 |
| Working Capital | 5.24M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -22.61M |
| Capital Expenditures | -6,660 |
| Depreciation & Amortization | 97,434 |
| Net Borrowing | 950,000 |
| Free Cash Flow | -22.61M |
| FCF Per Share | -$1.34 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -246.69% |
| Shareholder Yield | -246.69% |
| Earnings Yield | -3,133.54% |
| FCF Yield | -81.94% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | May 15, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:28 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |